Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Pre-steady-state Kinetics Reveal the Substrate Specificity and Mechanism of Halide Oxidation of Truncated Human Peroxidasin 1.

Paumann-Page M, Katz RS, Bellei M, Schwartz I, Edenhofer E, Sevcnikar B, Soudi M, Hofbauer S, Battistuzzi G, Furtmüller PG, Obinger C.

J Biol Chem. 2017 Mar 17;292(11):4583-4592. doi: 10.1074/jbc.M117.775213. Epub 2017 Jan 31.

2.

Immune Recognition of Citrullinated Proteoglycan Aggrecan Epitopes in Mice with Proteoglycan-Induced Arthritis and in Patients with Rheumatoid Arthritis.

Markovics A, Ocskó T, Katz RS, Buzás EI, Glant TT, Mikecz K.

PLoS One. 2016 Jul 28;11(7):e0160284. doi: 10.1371/journal.pone.0160284. eCollection 2016.

3.

Three-Quarters of Persons in the US Population Reporting a Clinical Diagnosis of Fibromyalgia Do Not Satisfy Fibromyalgia Criteria: The 2012 National Health Interview Survey.

Walitt B, Katz RS, Bergman MJ, Wolfe F.

PLoS One. 2016 Jun 9;11(6):e0157235. doi: 10.1371/journal.pone.0157235. eCollection 2016.

4.

Characterization and Localization of Citrullinated Proteoglycan Aggrecan in Human Articular Cartilage.

Glant TT, Ocsko T, Markovics A, Szekanecz Z, Katz RS, Rauch TA, Mikecz K.

PLoS One. 2016 Mar 4;11(3):e0150784. doi: 10.1371/journal.pone.0150784. eCollection 2016.

5.

The Polysymptomatic Distress Scale Is Simple, Useful, and Effective in Clinical Care and Clinical and Epidemiology Studies.

Wolfe F, Walitt BT, Rasker JJ, Katz RS, Häuser W.

J Rheumatol. 2016 Feb;43(2):454. doi: 10.3899/jrheum.150926. No abstract available.

PMID:
26834253
6.

The Prevalence and Characteristics of Fibromyalgia in the 2012 National Health Interview Survey.

Walitt B, Nahin RL, Katz RS, Bergman MJ, Wolfe F.

PLoS One. 2015 Sep 17;10(9):e0138024. doi: 10.1371/journal.pone.0138024. eCollection 2015.

7.

The Use of Polysymptomatic Distress Categories in the Evaluation of Fibromyalgia (FM) and FM Severity.

Wolfe F, Walitt BT, Rasker JJ, Katz RS, Häuser W.

J Rheumatol. 2015 Aug;42(8):1494-501. doi: 10.3899/jrheum.141519. Epub 2015 Jun 15.

8.

Cross-sectional neurocognitive data do not support a transition from fibrofog to Alzheimer disease in fibromyalgia patients.

Leavitt F, Katz RS.

J Clin Rheumatol. 2015 Mar;21(2):81-5. doi: 10.1097/RHU.0000000000000213.

PMID:
25710859
9.

Fibrofog and fibromyalgia: a narrative review and implications for clinical practice.

Kravitz HM, Katz RS.

Rheumatol Int. 2015 Jul;35(7):1115-25. doi: 10.1007/s00296-014-3208-7. Epub 2015 Jan 13. Review.

PMID:
25583051
10.

Cognitive dysfunction in fibromyalgia: slow access to the mental lexicon.

Leavitt F, Katz RS.

Psychol Rep. 2014 Dec;115(3):828-39. doi: 10.2466/04.15.PR0.115c32z1.

PMID:
25539171
11.

Identification of myeloid-derived suppressor cells in the synovial fluid of patients with rheumatoid arthritis: a pilot study.

Kurkó J, Vida A, Glant TT, Scanzello CR, Katz RS, Nair A, Szekanecz Z, Mikecz K.

BMC Musculoskelet Disord. 2014 Aug 19;15:281. doi: 10.1186/1471-2474-15-281.

12.

Fibromyalgia and physical trauma: the concepts we invent.

Wolfe F, Häuser W, Walitt BT, Katz RS, Rasker JJ, Russell AS.

J Rheumatol. 2014 Sep;41(9):1737-45. doi: 10.3899/jrheum.140268. Epub 2014 Aug 1. Review.

PMID:
25086080
13.

Bilateral vitreomacular traction resolved with a single intravitreal ocriplasmin injection.

Katz RS.

Ophthalmic Surg Lasers Imaging Retina. 2014 May-Jun;45(3):239-42. doi: 10.3928/23258160-20140401-01. Epub 2014 Apr 7.

PMID:
24708167
14.

Symptoms, the nature of fibromyalgia, and diagnostic and statistical manual 5 (DSM-5) defined mental illness in patients with rheumatoid arthritis and fibromyalgia.

Wolfe F, Walitt BT, Katz RS, Häuser W.

PLoS One. 2014 Feb 14;9(2):e88740. doi: 10.1371/journal.pone.0088740. eCollection 2014.

15.

Social security work disability and its predictors in patients with fibromyalgia.

Wolfe F, Walitt BT, Katz RS, Häuser W.

Arthritis Care Res (Hoboken). 2014 Sep;66(9):1354-63. doi: 10.1002/acr.22305.

16.

Polysymptomatic distress in patients with rheumatoid arthritis: understanding disproportionate response and its spectrum.

Wolfe F, Michaud K, Busch RE, Katz RS, Rasker JJ, Shahouri SH, Shaver TS, Wang S, Walitt BT, Häuser W.

Arthritis Care Res (Hoboken). 2014 Oct;66(10):1465-71. doi: 10.1002/acr.22300.

17.

Differentially expressed epigenome modifiers, including aurora kinases A and B, in immune cells in rheumatoid arthritis in humans and mouse models.

Glant TT, Besenyei T, Kádár A, Kurkó J, Tryniszewska B, Gál J, Soós G, Szekanecz Z, Hoffmann G, Block JA, Katz RS, Mikecz K, Rauch TA.

Arthritis Rheum. 2013 Jul;65(7):1725-35. doi: 10.1002/art.37986.

18.

How to read an explanation of benefits.

Katz RS.

J Clin Rheumatol. 2013 Mar;19(2):78. doi: 10.1097/RHU.0b013e31828684e0. No abstract available.

PMID:
23425668
19.

Longitudinal patterns of analgesic and central acting drug use and associated effectiveness in fibromyalgia.

Wolfe F, Walitt BT, Katz RS, Lee YC, Michaud KD, Häuser W.

Eur J Pain. 2013 Apr;17(4):581-6. doi: 10.1002/j.1532-2149.2012.00234.x. Epub 2012 Nov 21.

PMID:
23169685
20.

Development of the Mental Clutter Scale.

Leavitt F, Katz RS.

Psychol Rep. 2011 Oct;109(2):445-52.

PMID:
22238851
21.

The longitudinal outcome of fibromyalgia: a study of 1555 patients.

Walitt B, Fitzcharles MA, Hassett AL, Katz RS, Häuser W, Wolfe F.

J Rheumatol. 2011 Oct;38(10):2238-46. doi: 10.3899/jrheum.110026. Epub 2011 Jul 15.

PMID:
21765102
22.

Successful treatment of amegakaryocytic thrombocytopenia with eltrombopag in a patient with systemic lupus erythematosus (SLE).

Cela I, Miller IJ, Katz RS, Rizman A, Shammo JM.

Clin Adv Hematol Oncol. 2010 Nov;8(11):806-9. No abstract available.

PMID:
21326158
23.

Do we need core sets of fibromyalgia domains? The assessment of fibromyalgia (and other rheumatic disorders) in clinical practice.

Wolfe F, Hassett AL, Katz RS, Michaud K, Walitt B.

J Rheumatol. 2011 Jun;38(6):1104-12. doi: 10.3899/jrheum.100511. Epub 2011 Feb 1.

PMID:
21285168
24.

Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia.

Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Häuser W, Katz RS, Mease P, Russell AS, Russell IJ, Winfield JB.

J Rheumatol. 2011 Jun;38(6):1113-22. doi: 10.3899/jrheum.100594. Epub 2011 Feb 1.

PMID:
21285161
25.

The development of fibromyalgia--I: examination of rates and predictors in patients with rheumatoid arthritis (RA).

Wolfe F, Häuser W, Hassett AL, Katz RS, Walitt BT.

Pain. 2011 Feb;152(2):291-9. doi: 10.1016/j.pain.2010.09.027. Epub 2010 Oct 18.

PMID:
20961687
26.

The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity.

Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, Russell AS, Russell IJ, Winfield JB, Yunus MB.

Arthritis Care Res (Hoboken). 2010 May;62(5):600-10. doi: 10.1002/acr.20140.

27.

Development and initial validation of a self-assessed lupus organ damage instrument.

Costenbader KH, Khamashta M, Ruiz-Garcia S, Perez-Rodriguez MT, Petri M, Elliott J, Manzi S, Karlson EW, Turner-Stokes T, Bermas B, Coblyn J, Massarotti E, Schur P, Fraser P, Navarro I, Hanly JG, Shaver TS, Katz RS, Chakravarty E, Fortin PR, Sanchez ML, Liu J, Michaud K, Alarcón GS, Wolfe F.

Arthritis Care Res (Hoboken). 2010 Apr;62(4):559-68. doi: 10.1002/acr.20193.

28.
29.

EQ-5D and SF-36 quality of life measures in systemic lupus erythematosus: comparisons with rheumatoid arthritis, noninflammatory rheumatic disorders, and fibromyalgia.

Wolfe F, Michaud K, Li T, Katz RS.

J Rheumatol. 2010 Feb;37(2):296-304. doi: 10.3899/jrheum.090778. Epub 2009 Dec 23.

PMID:
20032098
30.

Efficacy of topical cyclosporine for the treatment of ocular rosacea.

Schechter BA, Katz RS, Friedman LS.

Adv Ther. 2009 Jun;26(6):651-9. doi: 10.1007/s12325-009-0037-2. Epub 2009 Jun 23.

PMID:
19551353
31.

Normalizing memory recall in fibromyalgia with rehearsal: a distraction-counteracting effect.

Leavitt F, Katz RS.

Arthritis Rheum. 2009 Jun 15;61(6):740-4. doi: 10.1002/art.24559.

32.

Evidence of concurrent immunopathological mechanisms determining the pathology of severe lupus nephritis.

Schwartz MM, Korbet SM, Katz RS, Lewis EJ.

Lupus. 2009 Feb;18(2):149-58. doi: 10.1177/0961203308095947.

PMID:
19151117
33.

Fibromyalgia, systemic lupus erythematosus (SLE), and evaluation of SLE activity.

Wolfe F, Petri M, Alarcón GS, Goldman J, Chakravarty EF, Katz RS, Karlson EW.

J Rheumatol. 2009 Jan;36(1):82-8. doi: 10.3899/jrheum.080212.

34.

Ecological correlates of risk and incidence of West Nile virus in the United States.

Allan BF, Langerhans RB, Ryberg WA, Landesman WJ, Griffin NW, Katz RS, Oberle BJ, Schutzenhofer MR, Smyth KN, de St Maurice A, Clark L, Crooks KR, Hernandez DE, McLean RG, Ostfeld RS, Chase JM.

Oecologia. 2009 Jan;158(4):699-708. doi: 10.1007/s00442-008-1169-9. Epub 2008 Oct 22.

PMID:
18941794
35.

Speed of mental operations in fibromyalgia: a selective naming speed deficit.

Leavitt F, Katz RS.

J Clin Rheumatol. 2008 Aug;14(4):214-8. doi: 10.1097/RHU.0b013e31817a2472.

PMID:
18636019
36.

Value of a complete or partial remission in severe lupus nephritis.

Chen YE, Korbet SM, Katz RS, Schwartz MM, Lewis EJ; Collaborative Study Group.

Clin J Am Soc Nephrol. 2008 Jan;3(1):46-53. Epub 2007 Nov 14.

37.
38.

Cognitive and dissociative manifestations in fibromyalgia.

Leavitt F, Katz RS, Mills M, Heard AR.

J Clin Rheumatol. 2002 Apr;8(2):77-84.

PMID:
17041327
39.

Distraction as a key determinant of impaired memory in patients with fibromyalgia.

Leavitt F, Katz RS.

J Rheumatol. 2006 Jan;33(1):127-32.

PMID:
16395760
40.
41.
42.

Subacute sclerosing panencephalitis: more cases of this fatal disease are prevented by measles immunization than was previously recognized.

Bellini WJ, Rota JS, Lowe LE, Katz RS, Dyken PR, Zaki SR, Shieh WJ, Rota PA.

J Infect Dis. 2005 Nov 15;192(10):1686-93. Epub 2005 Oct 12.

PMID:
16235165
43.

Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus.

Petri MA, Mease PJ, Merrill JT, Lahita RG, Iannini MJ, Yocum DE, Ginzler EM, Katz RS, Gluck OS, Genovese MC, Van Vollenhoven R, Kalunian KC, Manzi S, Greenwald MW, Buyon JP, Olsen NJ, Schiff MH, Kavanaugh AF, Caldwell JR, Ramsey-Goldman R, St Clair EW, Goldman AL, Egan RM, Polisson RP, Moder KG, Rothfield NF, Spencer RT, Hobbs K, Fessler BJ, Calabrese LH, Moreland LW, Cohen SB, Quarles BJ, Strand V, Gurwith M, Schwartz KE.

Arthritis Rheum. 2004 Sep;50(9):2858-68.

44.

Lack of evidence of measles virus shedding in people with inapparent measles virus infections.

Lievano FA, Papania MJ, Helfand RF, Harpaz R, Walls L, Katz RS, Williams I, Villamarzo YS, Rota PA, Bellini WJ.

J Infect Dis. 2004 May 1;189 Suppl 1:S165-70.

PMID:
15106106
45.

Endophthalmitis caused by Mycobacterium chelonae abscessus after intravitreal injection of triamcinolone.

Benz MS, Murray TG, Dubovy SR, Katz RS, Eifrig CW.

Arch Ophthalmol. 2003 Feb;121(2):271-3. No abstract available.

PMID:
12583797
46.

Molecular epidemiology of measles viruses in the United States, 1997-2001.

Rota PA, Liffick SL, Rota JS, Katz RS, Redd S, Papania M, Bellini WJ.

Emerg Infect Dis. 2002 Sep;8(9):902-8.

47.

Detection of measles virus RNA in whole blood stored on filter paper.

Katz RS, Premenko-Lanier M, McChesney MB, Rota PA, Bellini WJ.

J Med Virol. 2002 Aug;67(4):596-602.

PMID:
12116010
48.

Pre-treatment affinity for LJP 394 influences pharmacodynamic response in lupus patients.

McNeeley PA, Iverson GM, Furie RA, Cash JM, Cronin ME, Katz RS, Weisman MH, Aranow C, Linnik MD.

Lupus. 2001;10(8):526-32.

PMID:
11530993
49.

Treatment of systemic lupus erythematosus with LJP 394.

Furie RA, Cash JM, Cronin ME, Katz RS, Weisman MH, Aranow C, Liebling MR, Hudson NP, Berner CM, Coutts S, de Haan HA.

J Rheumatol. 2001 Feb;28(2):257-65.

PMID:
11246659
50.

Zafirlukast and Churg-Strauss syndrome.

Katz RS, Papernik M.

JAMA. 1998 Jun 24;279(24):1949; author reply 1950. No abstract available.

PMID:
9643848

Supplemental Content

Support Center